| Naslov: | Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy : subgroup safety analysis from the phase 3b CompLEEment-1 trial |
|---|
| Avtorji: | ID Borštnar, Simona (Avtor)
ID Palacova, Marketa (Avtor)
ID Łacko, Aleksandra (Avtor)
ID Timcheva, Constanta (Avtor)
ID Gal-Yam, Einav Nili (Avtor)
ID Papazisis, Konstantinos (Avtor)
ID Beniak, Juraj (Avtor)
ID Kudela, Pavol (Avtor)
ID Rubovszky, Gábor (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (462,13 KB)
MD5: B4B999D036C16F5550970C551FC25443
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2- ABC (MONALEESA-7). The multinational, phase 3b, CompLEEment-1 trial, which assessed the safety and efficacy of ribociclib plus letrozole in a broader population of patients who have not received prior endocrine therapy for advanced disease, is the largest phase 3 clinical trial to date to evaluate the safety and efficacy of a CDK4/6 inhibitor. We report a subanalysis of data from patients (N = 339) enrolled in the central and south European countries of the SERCE (Southern Europe, RUC, Central Europe) cluster of CompLEEment-1. Patients and methods: Men and women of any menopausal status with HR+/HER2- ABC received once-daily oral ribociclib 600 mg (3-weeks on/1-week-off), plus letrozole 2.5 mg continuously. Men/premenopausal women also received a GnRH-agonist. The primary outcome was the number of patients with adverse events (AEs) over a timeframe of approximately 36 months. Time-to-progression, overall response rate, and clinical benefit rate were also measured. Results: Safety results in the SERCE subgroup were consistent with those in the pivotal clinical trials of ribociclib in combination with endocrine therapy. Treatment-related AEs leading to dose adjustments/interruption occurred in 63.1% of patients but led to treatment discontinuation in only 10.6%. The most common treatment-related AEs of grade ≥ 3 were neutropenia and transaminase elevations. There were no fatal treatment-related events. Conclusions: These findings from the SERCE subgroup support the safety and manageable tolerability of ribociclib in a broad range of patients with HR+/HER2- ABC more representative of patients in real-world clinical practice. |
|---|
| Ključne besede: | CDK4/6 inhibitor, HER2−, HR+, advanced breast cancer, ribociclib |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Datum objave: | 01.01.2022 |
|---|
| Založnik: | Association of Radiology and Oncology |
|---|
| Leto izida: | 2022 |
|---|
| Št. strani: | str. 238-247 |
|---|
| Številčenje: | Vol. 56, no. 2 |
|---|
| Izvor: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-19763  |
|---|
| UDK: | 618.19-006 |
|---|
| ISSN pri članku: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2022-0020 |
|---|
| COBISS.SI-ID: | 108184835 |
|---|
| Avtorske pravice: | by Authors |
|---|
| Datum objave v DiRROS: | 24.07.2024 |
|---|
| Število ogledov: | 299 |
|---|
| Število prenosov: | 250 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
